Janice M Reichert Selected Research

fasinumab

1/2021	Antibodies to watch in 2021.
2/2018	Antibodies to watch in 2018.
2/2017	Antibodies to watch in 2017.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janice M Reichert Research Topics

Disease

24	Neoplasms (Cancer) 03/2024 - 01/2006
4	COVID-19 01/2023 - 07/2020
2	Hematologic Neoplasms (Hematological Malignancy) 01/2014 - 07/2012
2	Communicable Diseases (Infectious Diseases) 01/2013 - 12/2005
1	Coronavirus Infections 07/2020
1	Squamous Cell Carcinoma of Head and Neck 01/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2016
1	Multiple Myeloma 11/2016
1	Lung Diseases (Lung Disease) 08/2016
1	Respiratory Tract Diseases (Respiratory Tract Disease) 08/2016
1	Breast Neoplasms (Breast Cancer) 01/2014
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2014
1	Hodgkin Disease (Hodgkin's Disease) 01/2014
1	Osteoporosis 01/2013
1	Alzheimer Disease (Alzheimer's Disease) 01/2013
1	Clostridium Infections 01/2013
1	Lymphoma (Lymphomas) 07/2012

Drug/Important Bio-Agent (IBA)

19	AntibodiesIBA 01/2024 - 03/2011
7	Monoclonal AntibodiesIBA 08/2016 - 01/2006
5	Immunoconjugates (Immunoconjugate)IBA 02/2019 - 07/2012
3	Bispecific AntibodiesIBA 03/2024 - 01/2015
3	fasinumabIBA 01/2021 - 02/2017
3	Proteins (Proteins, Gene)FDA Link 07/2020 - 01/2012
3	ublituximabIBA 01/2020 - 02/2017
3	brolucizumabIBA 01/2020 - 02/2017
2	romosozumabIBA 01/2020 - 01/2015
2	risankizumabIBA 02/2018 - 02/2017
2	EmapalumabIBA 02/2018 - 02/2017
2	lampalizumabIBA 02/2018 - 02/2017
2	lanadelumabIBA 02/2018 - 02/2017
2	tanezumabIBA 02/2018 - 02/2017
2	eptinezumabIBA 02/2018 - 02/2017
2	glembatumumab vedotinIBA 02/2018 - 02/2017
2	bezlotoxumabIBA 01/2015 - 01/2013
2	actoxumabIBA 01/2015 - 01/2013
1	casirivimab and imdevimab drug combinationIBA 01/2021
1	bamlanivimabIBA 01/2021
1	ligelizumabIBA 01/2021
1	levilimabIBA 01/2021
1	itolizumabIBA 01/2021
1	tezepelumabIBA 01/2021
1	leronlimabIBA 01/2021
1	faricimabIBA 01/2021
1	Neutralizing AntibodiesIBA 07/2020
1	dostarlimabIBA 01/2020
1	margetuximabIBA 01/2020
1	belantamab mafodotinIBA 01/2020
1	enfortumab vedotinIBA 01/2020
1	loncastuximab tesirineIBA 01/2020
1	spartalizumabIBA 01/2020
1	balstilimabIBA 01/2020
1	pamrevlumabIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	sacituzumab govitecanIBA 02/2018
1	sintilimabIBA 02/2018
1	ravulizumabIBA 02/2018
1	satralizumabIBA 02/2018
1	tremelimumabIBA 02/2018
1	immunotoxin HA22IBA 02/2018
1	cemiplimabIBA 02/2018
1	crizanlizumabIBA 02/2018
1	etrolizumabIBA 02/2018
1	gantenerumabIBA 02/2018
1	isatuximabIBA 02/2018
1	carotuximabIBA 02/2018
1	anifrolumabIBA 02/2018
1	camrelizumabIBA 02/2018
1	birtamimabIBA 02/2018
1	mirvetuximab soravtansineIBA 02/2018
1	caplacizumabIBA 02/2017
1	tralokinumabIBA 02/2017
1	erenumabIBA 02/2017
1	durvalumabIBA 02/2017
1	anetumab ravtansineIBA 02/2017
1	fremanezumabIBA 02/2017
1	Cancer VaccinesIBA 11/2016
1	Fc Receptors (Fc Receptor)IBA 11/2016
1	daratumumabIBA 11/2016
1	racotumomabIBA 01/2015
1	bimagrumabIBA 01/2015
1	epratuzumabIBA 01/2015
1	gevokizumabIBA 01/2015
1	clivatuzumabIBA 01/2015
1	dupilumabIBA 01/2015
1	brodalumabIBA 01/2015
1	guselkumabIBA 01/2015
1	bococizumabIBA 01/2015
1	sirukumabIBA 01/2015
1	tildrakizumabIBA 01/2015
1	sarilumabIBA 01/2015
1	Ado-Trastuzumab EmtansineIBA 01/2014
1	Brentuximab VedotinIBA 01/2014
1	CholesterolIBA 01/2013
1	obinutuzumabIBA 07/2012
1	Biosimilar PharmaceuticalsIBA 07/2012
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2012
1	Peptides (Polypeptides)IBA 01/2012
1	Interleukin-17 (Interleukin 17)IBA 01/2012

Therapy/Procedure

20	Therapeutics 03/2024 - 05/2007
4	Immunotherapy 01/2016 - 03/2011